Skip to content

Price / book at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
1.5×-3.9×
Biogen logo
BiogenBIIB
1.4×+0.3×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
3.9×-0.5×
Insmed logo
InsmedINSM
50×-89.2×
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
3.5×+1.7×
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
6.1×+0.9×

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$910.66M+145%
Enterprise value$634.23M+244%
P/S112.5×-10.3×

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Where this comes from

Calculated from Solid Biosciences Inc.’s reported figures.

Based on the most recent quarter.

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solid Biosciences Inc.'s price / book?
Solid Biosciences Inc. (SLDB) reported price / book of 1.9× in Q1 2026.
How has Solid Biosciences Inc.'s price / book changed year-over-year?
Solid Biosciences Inc.'s price / book increased by 94.5% year-over-year, from 1× to 1.9×.
What is the long-term trend for Solid Biosciences Inc.'s price / book?
Over 5 years (2020 to 2025), Solid Biosciences Inc.'s price / book has grown at a -17.3% compound annual growth rate (CAGR), from 6.3× to 2.4×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.